For example, in the study conducted by Chapman et al. [6], patients were eligible for omalizumab if they exhibited allergic eosinophilic asthma characterized by elevated serum IgE levels within the range of X to Y IU/mL, coupled with a history of multiple asthma exacerbations despite standard treatment over the previous year. Here, IGHE is linked to asthma.